Company to advance M107 into Phase 2 clinical development in gastroparesis based on feedback from Pre-IND meeting with FDARADNOR, Pa. (BUSINESS WIRE) Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with.